Access these resources to learn more about the latest long-term outcomes data for larotrectinib in CNS and GI cancers, and to access an overview of the TAPISTRY platform trial. Prof Andrea Sartore-Bianchi (NTRK CONNECT) has developed this resource with COR2ED.


Hello I’m Andrea Sartore-Bianchi, a medical oncologist at Niguarda Hospital and University of Milan, Italy.

And I’m glad to provide you with this update about data regarding NTRK fusions as target of therapy from recent ASCO and World Congress on Gastrointestinal Cancer 2021.

There is indeed always interest around this agnostic target of cancer therapy and some relevant updates and new analysis have been presented in both congresses with a particular focus also on GI cancers.

First of all, at ASCO 21 an updated efficacy analysis for larotrectinib has been presented with a two years efficacy and safety follow up of the integrated data set from the three phase 1 and 2 trials previously presented. Now the total number of patients is more than 200, mainly sarcomas but also 5% colorectal cancer.

The main message from this data is that the majority of patients with TRK fusion cancer treated with larotrectinib had a long-term clinical benefit with very durable responses in PFS and OS and the safety profile continued to be favourable.

In this data set there were no CNS primary tumours but at the same congress, ASCO 2021, Dr Perreault presented data, instead of larotrectinib in the specific population of primary CNS tumour, and this is another important population, given the efficacy that we know that NTRK inhibitor has also in this setting.

In this analysis tumours were mainly high grade gliomas and also in this population larotrectinib induced tumour shrinkage in the majority of patients and rapid and durable responses with a high disease control rate and a favourable safety profile.

Now turning to the World Congress of Gastrointestinal Cancer, here we had presented by Dr Boni an interesting updated analysis on an expanded data set of GI tumours treated with larotrectinib. 18 patients had been presented and mostly presented with colorectal cancer. And now in colorectal cancer these patients were mainly MSI-high because it has been well confirmed, and now we know, that there is an enrichment for NTRK fusion in colorectal cancer that are RAS, BRAF wild type, MSI-high and MLH1 methylated. So these are those sporadic MSI-high tumours, and in this analysis, there were also cholangiocarcinoma and pancreatic cancer.

So the overall response rate has been confirmed to be 40% up to 50% in colorectal cancer and also here in this tumour type a complete response has been observed. The overall survival in the colorectal cancer cohort were also very long, approaching 30 months. And it is important to understand if this patient received also immunotherapy, being for the most part of them also MSI-high.

Finally, it should be mentioned that, at the ASCO Congress, also the trial design of the TAPISTRY trial is being presented by Dr Drilon. This is a novel platform, a phase 2 umbrella trial with target therapy or immunotherapy based on relevant oncogenic alterations and there is indeed a cohort of NTRK positive patients to be treated with entrectinib.

So overall, there is an interest, and these recent presentations highlight, I think, the importance of testing for NTRK gene fusions in patients with cancer. The majority of patients with this molecular alteration had long-term clinical benefit.  With TRK inhibitors there are also data regarding GI tumours now in particular MSI colorectal cancer. And this, I think, can add a valuable target also in this tumour type, in this specific subpopulation.

I thank you very much for your attention and I encourage you to visit the NTRK CONNECT website where you can find also a complete slide deck with all these presentations from ASCO and World Congress on Gastrointestinal Cancer, thank you.

This programme is supported by an Independent Educational Grant from Bayer

Andrea Sartore-Bianchi is the Director of the Division of Clinical Research and Innovation at Grande Ospedale Metropolitano Niguarda in Milano, Italy, and Associate Professor of Oncology at the University of Milano. He received his MD and postgraduate degree in Oncology at the University of Pavia, Italy, and subsequently conducted preclinical research at Brown University, Providence, RI, USA.

 

His main clinical and research interests include precision oncology and the treatment of gastrointestinal cancers, particularly colorectal carcinomas, focusing on biomarkers of sensitivity/resistance to targeted therapies. He is principal and co-investigator in Phase I-III clinical trials for solid tumours and carried out initial studies paving the way for the use of RAS and Her2 as tumor tissue/ctDNA biomarkers in colorectal cancer. He has published 200 peer-reviewed articles in various medical journals with a H-index of 62 (Scopus).

Prof. Andrea Sartore-Bianchi has received financial support/sponsorship for research support, consultation, or speaker fees from the following companies:

Amgen, Bayer, Sanofi and Servier Pharmaceuticals. 

Programme summary
Watch the video now
Share this programme
This educational programme is supported by an Independent Educational Grant from Bayer
Supporter Acknowledgement
This educational programme is supported by an Independent Educational Grant from Bayer
I agree that this educational programme:

Was valuable to me

1/4
Brought to you by
PRECISION ONCOLOGY CONNECT

PRECISION ONCOLOGY CONNECT is an initiative of COR2ED, supported by Independent Educational Grants from AstraZeneca, Amoy Diagnostics, Bayer, Pierre Fabre Laboratories and Thermo Fisher Scientific.

Meet the experts Independent IME approved

Other programmes of interest

conference-update Conference update
Oncology 
ER+ metastatic breast cancer: Highlights from the 13th APBCS Satellite Symposium

Medical experts discuss treatment strategies and sequencing after ET + CDK4/6i for ER+/HER2- metastatic breast cancer  

Experts
Prof. Shaheenah Dawood, Prof. Heather McArthur, Prof. Javier Cortés, Prof. Frédérique Penault-Llorca
  • download Downloadable
    Resources
  • clock 5 MIN
  • calendar Feb 2025

This programme has been sponsored by Menarini Stemline and is intended for healthcare professionals only.
podcast Podcast
Hemostasis and bleeding disorders Oncology 
Σειρά podcast για τη διαχείριση της θρόμβωσης

Αναλύσεις από καταξιωμένους ειδικούς ιατρούς. Πλοηγηθείτε στις καρτέλες για να επιλέξετε ένα επεισόδιο podcast

Experts
Prof. Dimitrios Tsakiris, Prof. Michael Nagler, Dr Lars Asmis, Prof. Jerzy Windyga
  • download Downloadable
    Resources
  • clock 27 MIN
  • calendar Feb 2025

This educational programme is supported by an Independent Educational Grant from Viatris.
conference-update Conference update
Oncology 
ESMO Virtual Plenary: Final OS results from the phase III TROPION-Breast01 trial

How will the latest Dato-DXd data impact treatment strategies for HR+/HER2− mBC?

Experts
Prof. François-Clément Bidard, Dr Barbara Pistilli
  • clock 5 MIN
  • calendar Feb 2025

Educational programme supported by an Independent Educational Grant from AstraZeneca
podcast Podcast
Oncology Obstetrics and Gynecology 
Advanced or recurrent endometrial cancer: Molecular classification and treatment decisions

Understanding the role of molecular subtypes in guiding treatment selection

Experts
Prof. Xavier Matias-Guiu, Dr Jurjees Hasan
Endorsed by
Biomarker Collaborative ICAN international cancer advocacy network
  • download Downloadable
    Resources
  • clock 11 MIN
  • calendar Feb 2025

This programme has been sponsored by Eisai Europe Limited ("Eisai"). Eisai has had no input on the educational content of, or speakers involved in this Video Podcast.
podcast Podcast
Hemostasis and bleeding disorders Oncology 
Postępowanie w przypadku zakrzepicy – seria podcastów

Uznani eksperci dzielą się swoimi spostrzeżeniami. Kliknij na odpowiednią zakładkę, aby wybrać odcinek podcastu.

Experts
Prof. Dimitrios Tsakiris, Prof. Michael Nagler, Dr Lars Asmis, Prof. Jerzy Windyga
  • download Downloadable
    Resources
  • clock 27 MIN
  • calendar Feb 2025

This educational programme is supported by an Independent Educational Grant from Viatris.
conference-update Conference update
Oncology 
Highlights from ASCO GI 2025

Expert insights on BRAF-mutated colorectal cancer

Experts
Dr Elena Élez
Endorsed by
DiCE BRAF Bombers ICAN international cancer advocacy network
Biomarker Collaborative
  • download Downloadable
    Resources
  • clock 5 MIN
  • calendar Feb 2025

Educational programme supported by an Independent Educational Grant from Pierre Fabre Laboratories. The programme is therefore independent, the content is not influenced by Pierre Fabre Laboratories and is under the sole responsibility of the experts. This content is intended for HCPs outside the UK and ROl only.